C07K 14/56
Ifn-alpha
Official title: IFN-alpha
C07K14/56 (Ifn-alpha) appears on 593 US grants and 777 published applications in this corpus.
Search patents in C07K- Granted patents
- 593
- Published applications
- 777
- Assignees
- 324
- Inventors
- 1,240
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 5 | 0 |
| 1985 | 5 | 0 |
| 1986 | 1 | 0 |
| 1987 | 10 | 0 |
| 1988 | 7 | 0 |
| 1989 | 7 | 0 |
| 1990 | 10 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 6 | 0 |
| 1994 | 3 | 0 |
| 1995 | 8 | 0 |
| 1996 | 6 | 0 |
| 1997 | 6 | 0 |
| 1998 | 19 | 0 |
| 1999 | 16 | 0 |
| 2000 | 8 | 0 |
| 2001 | 13 | 1 |
| 2002 | 15 | 11 |
| 2003 | 10 | 25 |
| 2004 | 9 | 30 |
| 2005 | 11 | 29 |
| 2006 | 9 | 30 |
| 2007 | 16 | 30 |
| 2008 | 23 | 42 |
| 2009 | 23 | 26 |
| 2010 | 27 | 31 |
| 2011 | 18 | 39 |
| 2012 | 15 | 24 |
| 2013 | 15 | 25 |
| 2014 | 11 | 54 |
| 2015 | 34 | 31 |
| 2016 | 20 | 30 |
| 2017 | 31 | 29 |
| 2018 | 17 | 27 |
| 2019 | 21 | 31 |
| 2020 | 18 | 42 |
| 2021 | 20 | 32 |
| 2022 | 18 | 31 |
| 2023 | 16 | 35 |
| 2024 | 15 | 39 |
| 2025 | 21 | 22 |
| 2026 | 12 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeting of human interferon antagonists22 Sep 2026US 12,741,998 B2Centre Hospitalier Regional Universitaire De Montpellier
- Pegylated porcine interferon and methods of use thereof16 Jun 2026US 12,653,897 B2Ambrx, Inc.
- Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 216 Jun 2026US 12,655,186 B2Orionis Biosciences BV
- Activatable cytokine polypeptides and methods of use thereof5 May 2026US 12,617,829 B2Werewolf Therapeutics, Inc.
- 5T4 single domain antibodies and therapeutic compositions thereof31 Mar 2026US 12,590,169 B2Inhibrx Biosciences, Inc.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Therapeutic interferon alpha 1 proteins10 Sep 2026US 2026/0265328 A1Orionis Biosciences BV
- Dosing of cd38-binding fusion protein10 Sep 2026US 2026/0265401 A1Takeda Pharmaceutical Company Limited
- Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production27 Aug 2026US 2026/0248914 A1
Most cited
By later US patents
- N-terminally chemically modified protein compositions and methods378US 5,824,784 AAmgen Inc. · 1998
- Methods and compositions for polypeptide engineering338US 6,586,182 B1Maxygen, Inc. · 2003
- Composition for introducing nucleic acid complexes into higher eucaryotic cells257US 5,547,932 ABoehringer Ingelheim International GmbH · 1996
- Peg-interferon conjugates243US 5,382,657 AHoffmann-La Roche Inc. · 1995
- Methods and compositions for polypeptide engineering217US 6,303,344 B1Maxygen, Inc. · 2001